Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

A sulfoxide compound and method of producing benzothiophene derivatives using the same are provided. The sulfoxide compound is represented by formula (I), wherein R.sub.1 and R.sub.2 are individually and independently benzoyl group; alkyl, acyl or silyl group of C.sub.1-C.sub.6 straight chain or branched chain; or alkenyl group of C.sub.3-C.sub.6 straight chain or branched chain; and X is halogen atom. The sulfoxide compound reacts with alkynyl compound, and then the synthesis efficiency of benzothiophene derivatives can be effectively increased. ##STR00001##

The invention relates to pyridazinone and pyridone compounds having formula (I) or (I′), and pharmaceutically acceptable salts, hydrates, and solvates thereof ##STR00001##
wherein R.sub.1/R.sub.4 and X and X.sub.3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38α MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation.

The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38α MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation.

The present specification relates to a heterocyclic compound represented by Formula 1, an organic electronic device including the heterocyclic compound in an organic active layer, and a method for manufacturing the organic electronic device.

The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38α MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation.

The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38α MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation.

The present specification relates to a heterocyclic compound represented by Formula 1, an organic electronic device including the heterocyclic compound in an organic active layer, and a method for manufacturing the organic electronic device.

The present disclosure relates to novel thiophene monoamine based organic-inorganic hybrid perovskites, and the method of making and using the novel organic-inorganic hybrid perovskites.